Table 1.
Demographic and background characteristics by treatment group
| Nateglinide + metformin n = 133 | Gliclazide + metformin n = 129 | |
|---|---|---|
| Age (years), mean ± sd | 62.0 ± 11.0 | 61.6 ± 10.1 |
| Range | 28–84 | 38–80 |
| Age group, n (%) | ||
| < 65 years | 70 (52.6) | 68 (52.7) |
| ≥ 65 years | 63 (47.4) | 61 (47.3) |
| Sex, n (%) | ||
| Male | 72 (54.1) | 65 (50.4) |
| Female | 61 (45.9) | 64 (49.6) |
| Race, n (%) | ||
| Caucasian | 131 (98.5) | 124 (96.1) |
| Black | 0 | 1 (0.8) |
| Asian/Chinese/Japanese | 0 | 2 (1.6) |
| Other | 2 (1.5) | 2 (1.6) |
| BMI (kg/m2), mean ± sd | 28.5 ± 3.5 | 29.5 ± 3.6 |
| Duration of diabetes (years), mean ± sd | 7.16 ± 6.30 | 6.70 ± 5.55 |
| Baseline HbA1c (%), mean ± sd | 7.67 ± 0.59 | 7.60 ± 0.58 |
| Baseline FPG (mmol/l), mean ± sd | 8.95 ± 1.49 | 8.73 ± 1.48 |